Jia Li

6743906, Jun 1, 2004

Oct 1, 1999

09/410416

Glen A. Evans - San Marcos CA
Steven Siqing Wang - The Woodlands TX
Edward D. Esplin - Dallas TX
Jia Ling Li - Dallas TX
Liying Huang - Guang Dong, CN

Board of Regents, The University of Texas - Austin TX

C07H 2104

536 235, 536 241, 536 242, 514 44

The present invention identifies the PPP2R1B gene, as a human tumor suppressor gene. Sequencing of the PPP2R1B revealed that the gene is located on human chromosome 11q22-24 and that gene were mutated in tumors and tumor cell lines, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in lung, colon, breast and cervical cancer cells. Methods for diagnosing and treating cancers related to this tumor suppressor also are disclosed.

6764822, Jul 20, 2004

Apr 3, 2000

09/541210

John M. Butler - Menlo Park CA
Jia Li - Union City CA
Joseph A. Monforte - Berkeley CA
Christopher H. Becker - Palo Alto CA

Sequenom, Inc. - San Diego CA

C12Q 168

435 6, 435 912, 436 94, 436173, 536 253, 536 254

The present invention is related to the fields of genetic mapping and genetic identity detection, including forensic identification and paternity testing. This invention is more specifically directed to the use of mass spectrometry to detect length variation in DNA nucleotide sequence repeats (including variants of common alleles), such as microsatellites and short tandem repeats, and to DNA sequences provided as primers for the analysis of DNA tandem nucleotide repeat polymorphisms at specific loci on specific chromosomes.

7790371, Sep 7, 2010

Apr 20, 2004

10/552641

Russell Gene Higuchi - Alameda CA, US
Gary Allen Peltz - Redwood City CA, US
Bonnie Fijal - Hillsborough NJ, US
Sunhee Kwon Ro - Foster City CA, US
Jia Li - Union City CA, US

Roche Molecular Systems, Inc. - Pleasanton CA

C12Q 1/68
C12P 19/34

435 6, 435 912

The present invention relates to polymorphisms of the FRZB gene and the analysis of nucleic acids thereof. The invention further relates to methods of predicting risks of certain conditions in individual and kits for the determination of such risks.

20030158187, Aug 21, 2003

Jan 30, 2003

10/354693

Dorothee Foernzler - Lenzburg, CH
Lara Hashimoto - Basle, CH
Jia Li - Union City CA, US
Eric Luedin - Liestal, CH
Andrew Sleight - Riedisheim, FR
Pierre Vankan - Basle, CH

C12Q001/68
A61K031/44
A61K031/541
A61K031/5377

514/227500, 435/006000, 514/235500, 514/357000

The present invention relates to a method for correlating single nucleotide polymorphisms in the preprotachykinin (NKNA) gene with the efficacy and compatibility of a pharmaceutically active compound administered to a human being. The invention further relates to a method for determining the efficacy and compatibility of a pharmaceutically active compound administered to a human being which method comprises determining at least one single nucleotide polymorphism in the NKNA gene. Said methods are based on determining specific single nucleotide polymorphisms in the NKNA gene and determining the efficacy and compatibility of a pharmaceutically active compound in the human by reference to polymorphism in NKNA. The invention further relates to isolated nucleic acids comprising within their sequence the polymorphisms as defined herein, to nucleic acid primers and oligonucleotide probes capable of hybridizing to such nucleic acids and to a diagnostic kit comprising one or more of such primers and probes for detecting a polymorphism in the NKNA gene, to a pharmaceutical pack comprising NK-1 receptor antagonists and instructions for administration of the drug to human beings tested for the polymorphisms as well as to a computer readable medium with the stored sequence information for the polymorphisms in the NKNA gene.

20060014187, Jan 19, 2006

Jun 28, 2005

11/170717

Jia Li - Union City CA, US
Russell Higuchi - Alameda CA, US
Sunhee Ro - Foster City CA, US
Gary Peltz - Redmond City CA, US

Roche Molecular Systems., Inc. - Alameda CA

C12Q 1/68
C12P 19/34

435006000, 435091200

The current invention is based on the discovery that the Prol2Ala and VN102 single nucleotide polymorphisms in the PPARγ2 provides a method of determining a susceptibility to osteoporosis by detecting the presence of PPARγ of the alleles.

20060228752, Oct 12, 2006

Jun 21, 2006

11/472083

Dorothee Foernzler - Lenzburg, CH
Lara Hashimoto - Basle, CH
Jia Li - Union City CA, US
Eric Luedin - Liestal, CH
Andrew Sleight - Riedisheim, FR
Pierre Vankan - Basle, CH

C12Q 1/68
A61K 31/5377
C07H 21/04

435006000, 514235200, 536023500

The present invention relates to a method for correlating single nucleotide polymorphisms in the preprotachykinin (NKNA) gene with the efficacy and compatibility of a pharmaceutically active compound administered to a human being. The invention further relates to a method for determining the efficacy and compatibility of a pharmaceutically active compound administered to a human being which method comprises determining at least one single nucleotide polymorphism in the NKNA gene. Said methods are based on determining specific single nucleotide polymorphisms in the NKNA gene and determining the efficacy and compatibility of a pharmaceutically active compound in the human by reference to polymorphism in NKNA. The invention further relates to isolated nucleic acids comprising within their sequence the polymorphisms as defined herein, to nucleic acid primers and oligonucleotide probes capable of hybridizing to such nucleic acids and to a diagnostic kit comprising one or more of such primers and probes for detecting a polymorphism in the NKNA gene, to a pharmaceutical pack comprising NK-1 receptor antagonists and instructions for administration of the drug to human beings tested for the polymorphisms as well as to a computer readable medium with the stored sequence information for the polymorphisms in the NKNA gene.

20130172389, Jul 4, 2013

Dec 27, 2012

13/727860

Ellen Chao - Irvine CA, US
Herman Ng - Tustin CA, US
Hau Ton - Buena Park CA, US
Jia Chian Li - Irvine CA, US
Joseph S. Adorante - Irvine CA, US
Michael S. Garst - Newport Beach CA, US
Howard B. Rind - Laguna Niguel CA, US
Mark R. Hansen - San Diego CA, US
Alfred Arthur Avey - Eugene OR, US
Lloyd Jay Dolby - Eugene OR, US
Shervin Esfandiari - Eugene OR, US
Vivian R. MacKenzie - Eugene OR, US
Jeremiah Andrew Marsden - Eugene OR, US
David Charles Muchmore - Eugene OR, US

Allegan, Inc. - Irvine CA

C07D 235/12
C07D 235/08
C07D 403/12
C07D 403/06
C07D 401/12
C07D 235/14
C07D 235/06

514338, 5483101, 514394, 5483097, 5483044, 5483061, 5462734, 5483057

The present invention is directed to a compound of Formula Ior a pharmaceutically acceptable salt thereof; wherein R, R, R, R, R, m, and n are as defined herein, to pharmaceutical compositions comprising said compound, and to methods of treating diseases or conditions mediated by elevated persistent sodium current, such as an ocular disorder, multiple sclerosis, seizure disorder, and chronic pain.

60905581, Jul 18, 2000

Sep 18, 1998

9/157177

John M. Butler - Menlo Park CA
Jia Li - Union City CA
Joseph A. Monforte - Berkeley CA
Christopher H. Becker - Palo Alto CA

Genetrace Systems, Inc. - Alameda CA

C07H 2104
C12P 1934
C12Q 168

435 6

The present invention is related to the fields of genetic mapping and genetic identity detection, including forensic identification and paternity testing. This invention is more specifically directed to the use of mass spectrometry to detect length variation in DNA nucleotide sequence repeats (including variants of common alleles), such as microsatellites and short tandem repeats, and to DNA sequences provided as primers for the analysis of DNA tandem nucleotide repeat polymorphisms at specific loci on specific chromosomes.